glp-1 incretin PDB-101: Molecule of the Month: Incretins Incretins as Multi–Disease State Treatments

Nassif, S

The PIONEER-6 trial primarily evaluated the cardiovascular safety of oral semaglutide (14 mg) in comparison to placebo (Husain et al., 2019)

Figure 1 gives an overview of the physiological actions of GLP-1 and GIP on various organ systems (47)

The Future The future is bright for GLP-1 agonists and their close relatives

More than diabetes and weight management Takeaways: This article is about the expanding role of glucagon-like peptide-1 receptor agonists (GLP-1s) beyond treating type 2 diabetes and obesity

When patients talk about GLP-1 and peptides for weight loss , it often reflects the same idea: using targeted, hormone-mimicking signals to reduce cravings and support metabolic health, so lifestyle changes are easier to maintain